年度乳腺X线筛查相比 biennial 筛查与更低分期乳腺癌相关
该回顾性队列研究纳入2016-2017年490例乳腺癌患者,其中245例可确定筛查频率(年度200例、 biennial 32例、 triennial 13例)。年度筛查组晚期分期比例、间期癌比例及平均肿瘤直径均显著低于 biennial 和非年度筛查组。结论认为年度乳腺X线筛查与更低乳腺癌分期和更少间期癌相关。
要点
- 年度筛查组晚期(II-IV期)比例24.0%,显著低于 biennial 组43.8%(p=.02)和非年度组44.4%(p=.006)。
- 年度筛查组间期癌比例10.5%,显著低于 biennial 组37.5%和非年度组33.3%(均p<.001)。
- 年度筛查组平均肿瘤直径1.4±1.2 cm,小于 biennial 组1.8±1.6 cm(p=.04)和非年度组1.8±1.5 cm(p=.03)。
核心结论
- 年度乳腺X线筛查相比 biennial 或非年度筛查,与更低乳腺癌分期、更少间期癌和更小肿瘤直径相关。
- 在绝经后女性中,年度筛查同样保持更低AJCC分期、更少间期癌和更小肿瘤直径。
- biennial 和非年度筛查组腋窝淋巴结清扫和化疗使用率数值更高,但差异无统计学意义。
研究设计与样本
- 回顾性、IRB批准、HIPAA合规的队列研究,查询乳腺癌数据库纳入2016-2017年经乳腺X线或临床诊断的乳腺癌患者。
- 总诊断490例,其中245例可确定筛查频率且年龄40-84岁(平均61.8±9.9岁,中位62岁)。
- 筛查频率:年度200例(81.6%)、 biennial 32例(13.1%)、 triennial 13例(5.3%)。
- 统计方法:连续变量用t检验或Wilcoxon秩和检验,分类变量用卡方或Fisher精确检验。
诊断标准与关键数值
- 晚期分期(AJCC II、III或IV期):年度筛查48/200(24.0%) vs biennial 14/32(43.8%),p=.02; vs 非年度20/45(44.4%),p=.006。
- 间期癌:年度筛查21/200(10.5%) vs biennial 12/32(37.5%),p<.001; vs 非年度15/45(33.3%),p<.001。
- 平均肿瘤直径:年度1.4±1.2 cm vs biennial 1.8±1.6 cm,p=.04; vs 非年度1.8±1.5 cm,p=.03。
- 腋窝淋巴结清扫:年度24/200(12.0%)、 biennial 6/32(18.8%)、非年度7/45(15.6%),差异无统计学意义。
- 化疗:年度55/200(27.5%)、 biennial 12/32(37.5%)、非年度16/45(35.6%),差异无统计学意义。
临床应用与阅片要点
- 阅片和报告时可关注筛查频率信息,年度筛查者晚期分期和间期癌比例更低。
- 间期癌在 biennial 和非年度筛查组更常见,提示筛查间隔可能影响间期癌发生。
- 肿瘤直径更小见于年度筛查组,提示规律年度筛查可能有助于早期发现。
局限性
- 回顾性队列研究设计。
- 单中心数据库查询,样本量有限(245例可评估筛查频率)。
- biennial 和 triennial 组样本量较小(分别为32例和13例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE. The purpose of this study was to compare breast cancer characteristics and treatment regimens among women undergoing annual versus nonannual screening mammography. MATERIALS AND METHODS. In this retrospective, institutional review board-approved, HIPAA-compliant cohort study, a breast cancer database was queried for patients who received a mammographic or clinical diagnosis of breast cancer during 2016-2017. Annual versus biennial and annual versus nonannual (biennial and triennial) mammography screening cohorts were compared using t tests or Wilcoxon rank sum tests for continuous variables and chi-square or Fisher exact tests for categoric variables. RESULTS. A total of 490 patients were diagnosed with breast cancer during 2016-2017. Among these women, 245 had an assignable screening frequency and were 40-84 years old (mean, 61.8 ± 9.9 [SD] years; median, 62 years). Screening frequency was annual for 200 of these 245 patients (81.6%), biennial for 32 (13.1%), and triennial for 13 (5.3%). Annual screening resulted in fewer late-stage presentations (AJCC stage II, III, or IV in 48 of 200 patients undergoing annual [24.0%] vs 14 of 32 undergoing biennial [43.8%; p = .02] and vs 20 of 45 undergoing nonannual screening [44.4%; p = .006]), fewer interval cancers (21 of 200 for annual [10.5%] vs 12 of 32 for biennial [37.5%; p < .001] and vs 15 of 45 for nonannual [33.3%; p < .001]), and smaller mean tumor diameter (1.4 ± 1.2 cm for annual vs 1.8 ± 1.6 cm for biennial [p = .04] and vs 1.8 ± 1.5 cm nonannual [p = .03]). Lower AJCC stage, fewer interval cancers, and smaller tumor diameter also persisted among postmenopausal women undergoing annual screening. Patients undergoing biennial and nonannual screening showed nonsignificant greater use of axillary lymph node dissection (annual, 24 of 200 [12.0%]; biennial, 6 of 32 [18.8%]; nonannual, 7 of 45 [15.6%]) and chemotherapy (annual, 55 of 200 [27.5%]; biennial, 12 of 32 [37.5%]; nonannual, 16 of 45 [35.6%]). CONCLUSION. Annual mammographic screening was associated with lower breast cancer stage and fewer interval cancers than biennial or nonannual screening.
引用
- Moorman SEH, Pujara AC, Sakala MD, et al. Annual Screening Mammography Associated With Lower Stage Breast Cancer Compared With Biennial Screening. AJR Am J Roentgenol. 2021. PMID: 33955776. doi:10.2214/AJR.20.23467
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。